Oppenheimer Reiterates Outperform on ArriVent BioPharma, Raises Price Target to $50
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
Oppenheimer analyst Jeff Jones reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and raises the price target from $44 to $50.
Oppenheimer analyst Jeff Jones reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and raises the price target from $44 to $50.